GSK's shingles vaccine approved for use in China in adults aged 50 and above
(Reuters) - GlaxoSmithKline Plc said on Thursday its shingles vaccine had been approved for use in China in adults aged 50 and above.
Shingrix, which has already been approved for use in the European Union, the United States, Canada, Japan and Australia, brought in 357 million pounds ($452.03 million) in the latest quarter.
The approval comes after China included the vaccine in a list of 48 “clinically urgently needed new medicines” designated for faster review.
MAY 23, 2019https://www.reuters.com/